Jeltje F. de Vries

Effect of Pembrolizumab After Stereotactic Body Radiotherapy vs Pembrolizumab Alone on Tumor Response in Patients With Advanced Non–Small Cell Lung Cancer

Willemijn S.M.E. Theelen, Heike Peulen, Ferry Lalezari et al. · JAMA Oncology · 2019 · 935 citations · Full text

Programmed Death 1 Blockade With Nivolumab in Patients With Recurrent Malignant Pleural Mesothelioma

Josine M.M.F. Quispel-Janssen, Vincent van der Noort, Jeltje F. de Vries et al. · Journal of Thoracic Oncology · 2018 · 244 citations · Full text

Ipilimumab and nivolumab in the treatment of recurrent malignant pleural mesothelioma (INITIATE): results of a prospective, single-arm, phase 2 trial

Maria Disselhorst, Josine M.M.F. Quispel-Janssen, Ferry Lalezari et al. · The Lancet Respiratory Medicine · 2019 · 243 citations

Oncology, Pleural Disease, Cancer Treatment +2

The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells

Jeltje F. de Vries, C. Michel Zwaan, Maaike de Bie et al. · Leukemia · 2011 · 114 citations

Hematological Malignancy, Medicine, Immunology +7

New cellular markers at diagnosis are associated with isolated central nervous system relapse in paediatric B‐cell precursor acute lymphoblastic leukaemia

Vincent H. J. van der Velden, Daphne de Launaij, Jeltje F. de Vries et al. · British Journal of Haematology · 2015 · 57 citations